GlassScriptPhysician profile
Damon Harley Helms
NPI 1033581699
$14,181.57
in general payments reported to CMS, 2019-2025
42 companies · $502 in 2025
The $502 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,490 · 2020: $2,960 · 2021: $4,958 · 2022: $1,549 · 2023: $236 · 2024: $487 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,392.21 | 2019-2022 | |
| Lilly USA, LLC | $1,366.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,035.03 | 2019-2023 | |
| Novo Nordisk INC | $975.39 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $962.87 | 2019-2022 | |
| Mannkind Corporation | $939.57 | 2019-2025 | Afrezza |
| Amarin Pharma, INC. | $884.34 | 2019-2022 | |
| Amgen INC. | $745.41 | 2019-2024 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.56 | 2019-2022 | |
| Corcept Therapeutics | $489.17 | 2020-2025 | Korlym |
| Zealand Pharma US, INC. | $441.97 | 2020-2022 | |
| Insulet Corporation | $436.96 | 2019-2022 | |
| Esperion Therapeutics, INC. | $411.70 | 2020-2021 | |
| Abbott Laboratories | $331.87 | 2021-2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $296.06 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Helms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.